retatrutide trial phase Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP New GLP-3 drug significantly slashes

Studied as a long-acting GH secretagogue mimicking

In the kidneys, GLP-1RAs lower urea, creatinine, and pro-inflammatory cytokines via AMPK-dependent pathways, supporting renal function during sepsis-induced acute kidney injury

Removing the injection requirement is a bigger deal than it sounds

Note: We recommend in-person lab work because at-home options often result in varying degrees of accuracy

While its impossible to quantify the potency loss without lab analysis, the risk of using a compromised compound is too high

[DOI] [PubMed] [Google Scholar] 283.Rodriguez P.J., Goodwin Cartwright B.M., Gratzl S., Brar R., Baker C., Gluckman T.J., Stucky N.L